Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0ICCWP)
| ADC Name |
Elatatug vedotin
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
TORL-2-307; TORL-2-307-ADC; CLDN18.2-307-ADC
Click to Show/Hide
|
|||||
| Organization |
TORL Biotherapeutics (Originator);University of California, Los Angeles
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-CLDN18.2 antibody
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma | ||||
| Gastric cancer | ||||
| Pancreatic cancer | ||||
| Unspecific solid tumor |
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients had advanced solid tumors (RECIST v1.1 measurable), ECOG 0-1, and adequate organ function. Exclusions included: unresolved toxicities (>Grade 1); recent anticancer therapy (14 days small molecule/28 days biologic); active brain metastases; uncontrolled comorbidities; cardiac disease; MDS/AML history; secondary malignancies (except curatively treated skin/DClS/low-risk prostate cancer); pregnancy/breastfeeding.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05156866 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer | ||||
| Primary Endpoint |
Safety assessments included AE/SAE incidence (NCI-CTCAE v5.0 graded) over 2 years, with MTD determined as the highest dose causing <33% DLTs among 6 evaluable participants in cycle 1 (28 days). RP2D derived from MTD, safety, and PK data.
|
||||
| Other Endpoint |
Efficacy measures (ORR/DOR/PFS/TTR) followed RECIST 1.1 over 2 years, with 1-/2-year OS rates tracked. PK profiles (Cmax/Cmin/Tmax/t1/2/AUC/Vz/CL/Rac) for TORL-2-307-ADC were analyzed at steady state (63 days) and single-dose (21 days). ADA positivity was monitored.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05156866 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1, first in human, dose-escalation study of TORL-2-307-ADC in participants with advanced cancer. | ||||
References